Palisade Bio Inc, a dedicated biopharmaceutical company committed to pioneering therapeutics for serious chronic gastrointestinal (GI) diseases, has witnessed a remarkable upswing in its stock value following the presentation of encouraging preclinical data at the recent Crohn’s & Colitis Congress in Las Vegas. The company’s lead asset, PALI-2108, a locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug, has shown promise in the treatment of moderate-to-severely active ulcerative colitis (UC).
The revelation of positive preclinical data has translated into a significant surge in thee stock value of Palisade Bio. Opening trading at $1.17 on Monday, the stock experienced a substantial leap from its previous closing value of $0.52.
At the time of this publication, Palisade Bio Inc stock (PALI) has witnessed a surge.
Palisade Bio Inc
Current Price: $1.05
Change : +0.53
Change (%): (101.92%)
Volume: 112.9M
Source: Tomorrow Events Market Data
The surge follows the unveiling of data in a poster presentation titled “Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment” at the esteemed congress. The full poster is available on the Scientific Publications page of the Company’s website.
Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, expressed enthusiasm about PALI-2108, stating, “PALI-2108 continues to demonstrate promise as a novel therapy for UC, with colon-selective bioactivation, an expanded therapeutic window, reduced CNS toxicity, potent PDE4 inhibitory activity, and impressive efficacy in preclinical models.” He further emphasized the company’s commitment to advancing UC treatment and making a meaningful impact for patients.
The preclinical studies presented at the Crohn’s and Colitis Congress showcased PALI-2108’s unique design and its potential to address the limitations of existing PDE4 inhibitors. Notably, the studies demonstrated significant outcomes in a DSS-induced UC mouse model, with a marked reduction in disease activity index (DAI) scores over time compared to the control group. Importantly, PALI-2108 displayed colon-specific distribution with minimal systemic exposure, addressing concerns related to CNS toxicity and systemic distribution that often lead to therapy discontinuation.
The innovative design of PALI-2108, featuring a galactose-derived sugar moiety, ensures minimal absorption until cleaved by the colonic bacterium enzyme β-glucuronidase. This design facilitates localized bioactivation, leading to colon-specific distribution, as confirmed by tissue distribution studies. The results of the colon/plasma AUC ratio exceeding 200 underscore PALI-2108’s preference for the colon.
Furthermore, the studies revealed colon-selective bioactivation in oxazolone colitis-induced mice, negligible plasma levels in duodenal and ileal tissue, and comparable target engagement with other PDE4 inhibitors. Importantly, a tolerated dose study in dogs demonstrated no CNS toxicity or emesis over effective doses, addressing critical concerns associated with oral administration.
Dr. Jones summarized the key findings, stating, “PALI-2108 is emerging as a promising candidate for UC therapy, offering localized bioactivation, expanded therapeutic window, and potent PDE4 inhibitory activity. We believe this innovative approach has the potential to revolutionize UC treatment and enhance patient outcomes.”
In conclusion, Palisade Bio Inc.’s preclinical studies on PALI-2108 have demonstrated local bioactivation, colon-specific distribution, similar target engagement to other PDE4 inhibitors, dose-dependent efficacy in a mouse UC model, and no systemic toxicity in dogs, highlighting a large therapeutic window due to local activation.
The positive developments come at a time when the inflammatory bowel disease (IBD) market represents a multi-billion-dollar opportunity in need of innovative approaches. Current therapies for IBD have achieved a clinical remission rate of less than 20% on average, underscoring the urgency for groundbreaking solutions. Palisade Bio Inc.’s strides in the development of PALI-2108 position the company as a notable player in the pursuit of transformative therapies for UC, potentially reshaping the landscape of IBD treatment. Investors and stakeholders are now eagerly anticipating the initiation of the Phase 1 study later this year, as the company continues its journey toward advancing UC treatment and improving patient outcomes.
